Ardelyx Company Profile (NASDAQ:ARDX)

Analyst Ratings

Consensus Ratings for Ardelyx (NASDAQ:ARDX) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.38 (105.92% upside)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016WedbushReiterated RatingOutperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Ladenburg ThalmannInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015BTIG ResearchInitiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Ardelyx (NASDAQ:ARDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.02)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015($0.06)($0.21)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014$1.83$0.44ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ardelyx (NASDAQ:ARDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.73)($0.74)
Q2 20162($0.67)($0.66)($0.67)
Q3 20162($0.70)($0.63)($0.67)
Q4 20162($0.65)($0.63)($0.64)
Q1 20171($0.72)($0.72)($0.72)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.75)($0.75)($0.75)
Q4 20171$0.78$0.78$0.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ardelyx (NASDAQ:ARDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ardelyx (NASDAQ:ARDX)
DateHeadline
07/21/16 01:58 PMInvestors Scour Big Pharma M&A Scene for Next Big Takeover -
07/20/16 05:07 AMARDELYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
07/16/16 10:16 AMKILL Robbins Arroyo LLP: Acquisition of Ardelyx, Inc. (ARDX) by Multiple Acquirers (Private) May Not Be in Shareholders' Best Interests
07/15/16 02:13 PMRobbins Arroyo LLP: Acquisition of Ardelyx, Inc. (ARDX) by Multiple Acquirers (Private) May Not Be in Shareholders' Best Interests - [Business Wire] - Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Ardelyx, Inc. by Deerfield Management Co LP, First Manhattan Co, DAFNA Capital Management LLC, RA Capital Management LLC, Cormorant Asset Management LLC, Rock Springs Capital Management LP, New Enterprise Associates, Australia's Future Funs, Quadrille Capital, EcoR1 Capital, and Perceptive Advisors .
07/15/16 07:28 AMArdelyx to Raise $110 Million in a Private Placement - [at noodls] - FREMONT, Calif., July 15, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has ...
07/15/16 07:09 AMARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition -
07/12/16 05:51 AMArdelyx (ARDX) Shares March Higher, Can It Continue? -
06/23/16 10:21 AMArdelyx (ARDX) Updates on RDX227675, Tenapanor Progress
06/22/16 07:21 AMArdelyx Reports Positive Results From End-of-Phase 2 Meeting With FDA
06/22/16 06:19 AMArdelyx Reports Progress of Development Programs - [at noodls] - FREMONT, Calif., June 22, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced updates to ...
06/22/16 06:03 AM7:03 am Ardelyx updates on two of its ongoing development programs, discloses positive results from End-of-Phase 2 meeting with the FDA -
06/07/16 08:18 AMArdelyx Appoints Robert Bazemore to Its Board of Directors - [at noodls] - FREMONT, Calif., June 7, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert ...
06/03/16 04:14 PMARDELYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 08:25 AMArdelyx to Present at 2016 BIO International Convention - [at noodls] - FREMONT, Calif., June 3, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Jeremy ...
05/17/16 12:04 PMARDELYX, INC. Financials -
05/10/16 09:22 AMEdited Transcript of ARDX earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 04:18 PMARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/09/16 04:03 PMARDELYX, INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 03:30 PMArdelyx Inc Earnings Call scheduled for 4:30 pm ET today -
05/09/16 03:13 PMArdelyx reports 1Q loss -
02/25/16 06:00 AMArdelyx to Report Fourth Quarter and Full Year 2015 Financial Results on March 4th, 2016 - [PR Newswire] - FREMONT, Calif., Feb. 25, 2016 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2015, on Friday, March 4, 2016. Following the announcement, the Ardelyx management team will host a live conference call and webcast at 8:00am ET to review the Company's financial results and provide a business update. The live webcast can be accessed by visiting the investor section of Ardelyx's website at ir.ardelyx.com.
02/02/16 03:15 PMArdelyx to Present at the 2016 Leerink Partners Global Healthcare Conference - [PR Newswire] - FREMONT, Calif., Feb. 2, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and renal diseases, today announced that Mike Raab, President ...
02/02/16 01:06 PMArdelyx Becomes Oversold (ARDX) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Ardelyx Inc (ARDX) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $9.99 per share. By comparison ...
01/13/16 03:50 PMArdelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares - [at noodls] - , /PRNewswire/ -- (: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public ...
01/13/16 03:42 PMARDELYX, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
01/11/16 06:30 AMArdelyx, Inc. (NASDAQ: ARDX) Analyst Coverage Initiated - [Accesswire] - FREMONT, CA / ACCESSWIRE / January 11, 2016 / Ardelyx, Inc. (NASDAQ: ARDX) a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, recently announced the positive ...
01/08/16 10:25 AMArdelyx Gears Up for Secondary Offering -
01/07/16 08:23 PMArdelyx Announces Pricing of Public Offering of Common Stock - [at noodls] - , /PRNewswire/ -- (: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 ...
01/06/16 03:57 PMArdelyx Announces Proposed Public Offering of Common Stock - [at noodls] - , /PRNewswire/ -- (: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of up ...
01/06/16 03:47 PMARDELYX, INC. Files SEC form 8-K, Other Events -
01/05/16 05:16 AMArdelyx Reports Positive Clinical Results of RDX022 for the Treatment of Hyperkalemia - [at noodls] - , /PRNewswire/ -- (: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating ...
01/04/16 07:38 AMArdelyx Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer - [at noodls] - , /PRNewswire/ -- (: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that , MD, MBA, joined the Company in a newly created position ...

Social

About Ardelyx

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal, GI and metabolic diseases. The Company utilizing its platform, discovered and designed its lead product candidate, tenapanor, which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca, has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development, such as RDX002 for the treatment of Hyperphosphatemia, RDX009 for the treatment of IBD, Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH), and RDX013 for the treatment of hyperkalemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDX
  • CUSIP:
Key Metrics:
  • Previous Close: $10.38
  • 50 Day Moving Average: $8.96
  • 200 Day Moving Average: $8.88
  • P/E Ratio: N/A
  • P/E Growth: -0.11
  • Market Cap: $359.46M
  • Beta: -0.16
  • Current Year EPS Consensus Estimate: $-2.8 EPS
  • Next Year EPS Consensus Estimate: $-2.23 EPS
Additional Links:
Ardelyx (NASDAQ:ARDX) Chart for Tuesday, July, 26, 2016